Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by JLGeminion Mar 16, 2011 3:22pm
278 Views
Post# 18294806

Cravenraven Prediction of $5.75

Cravenraven Prediction of $5.75

Cravenraven predicted $5.75.  He knew the strength of the buy side manipulation.  ONC was hit with a sale of 90,000 shares this afternoon to generate the low of $5.52.  The sale of 90,000 shares does not represent a retail holding.  The smart institutional money is buying by generating fear in retail investor minds.  Note the number of posters, like Cravenraven, who are happy that their stocks are losing money and espouse the market price being above suspicion.  Hold onto your shares and take advantage of the opportunity of buying ONC and ONCY on sale.

 

Remember the trading of Dendreon in April 2009.  The smart money was not taken by surprise as they depressed the price until the last day.

 

Date

Closing Price

Volume

1-Apr-09

$4.14

3,199,650

2-Apr-09

4.34

2,427,867

3-Apr-09

5.99

22,497,200

6-Apr-09

6.58

19,585,750

7-Apr-09

6.58

7,346,062

8-Apr-09

6.37

5,392,639

9-Apr-09

6.30

4,234,697

13-Apr-09

7.30

12,775,310

14-Apr-09

16.99

65,120,890

15-Apr-09

17.17

19,294,060

16-Apr-09

17.03

6,894,881

17-Apr-09

17.99

17,799,470

20-Apr-09

19.52

17,724,250

21-Apr-09

19.74

11,008,510

22-Apr-09

20.12

7,358,435

23-Apr-09

20.33

6,123,418

24-Apr-09

20.08

7,393,327

27-Apr-09

21.55

18,569,850

28-Apr-09

11.81

28,070,740

29-Apr-09

22.94

48,235,790

30-Apr-09

21.20

17,468,950

Yesterday

 

 

15-Mar-11

$34.61

3,079,175

 

Bullboard Posts